Ligand Pharmaceuticals (LGND) Share-based Compensation (2010 - 2025)
Ligand Pharmaceuticals (LGND) reported Share-based Compensation of -$23.0 million for Q4 2025, down 158.44% on a YoY basis from $39.3 million in Q4 2024, and down 255.84% sequentially from $14.7 million in Q3 2025.
Ligand Pharmaceuticals (LGND) Share-based Compensation (2010 - 2025) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 16 years of Share-based Compensation data on file, last reported at -$23.0 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 158.44% year-over-year to -$23.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 97.34% YoY), and the FY2025 full-year result was $9.6 million, down 76.64% from the prior year.
- Share-based Compensation eased to -$23.0 million in Q4 2025, from $14.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $39.3 million in Q4 2024 to a low of -$31.1 million in Q4 2022.
- A 5-year average of $4.4 million and a median of $5.9 million in 2021 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation sank 7025.0% in 2023 and surged 366.19% in 2024, its largest moves.
- Tracing LGND's Share-based Compensation over 5 years: stood at -$22.4 million in 2021, then sank by 39.29% to -$31.1 million in 2022, then jumped by 86.66% to -$4.2 million in 2023, then jumped by 1046.33% to $39.3 million in 2024, then sank by 158.44% to -$23.0 million in 2025.
- Business Quant data shows LGND's Share-based Compensation at -$23.0 million in Q4 2025, $14.7 million in Q3 2025, and $10.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -22.98 Mn |
| Dec 31, 2025 | -22.98 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 828,000.00 |
| Mar 31, 2025 | 828,000.00 |
| Dec 31, 2024 | 39.32 Mn |
| Dec 31, 2024 | 39.32 Mn |
| Sep 30, 2024 | 15.17 Mn |
| Sep 30, 2024 | 15.17 Mn |
| Jun 30, 2024 | 11.06 Mn |
| Jun 30, 2024 | 11.06 Mn |
| Jun 30, 2023 | -4.16 Mn |
| Jun 30, 2023 | -4.16 Mn |
| Mar 31, 2023 | 4.16 Mn |
| Mar 31, 2023 | 4.16 Mn |
| Dec 31, 2022 | -31.14 Mn |
| Dec 31, 2022 | -31.14 Mn |